Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-011213

CHIEF SCIENTIFIC OFFICER sold 5,000 shares at an average $16.07 ($80,366)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-04-21 Sale : show line 1 in the form 10b5-1 −4,670 $16.03 $74,848 998,018 I
2025-04-21 Sale : show line 2 in the form 10b5-1 −330 $16.72 $5,518 997,688 I
Open-market sales · 5,000 sh · avg $16.07 · $80,366
Loading xslF345X05/form4-04232025_090427.xml…